At a glance
ClinicalIndex Comparison RecordN/ACompleted· 265 enrolled
Drug / intervention
μCordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Benefits of Microcor in Ambulatory Decompensated Heart Failure
In Brief
A clinical study evaluating μCor for Heart Failure. Completed, enrolled 265 participants across 83 sites in 4 countries.
Detailed Summary
To assess investigator engagement of μCor system data in the context of heart failure management. The μCor system includes a sensor and wearable patch for fluid management.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesAustria, France, Germany, United States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartNov 2019
Primary CompletionJun 2023
Study CompletionOct 2023
TodayJul 2026
First PostedSep 19, 2019
Enrollment StartNov 1, 2019
Primary CompletionJun 30, 2023
Study CompletionOct 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.8 years ago
Interventions
μCordevice
μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.